Kyle Faget Authors Article on Clinical Trial Agreement Considerations for Pharmaceutical Sponsors
13 January 2022
Foley & Lardner LLP Partner Kyle Faget authored an article, “Clinical Trial Agreement Considerations for Pharmaceutical Sponsors,” for LexisNexis Practical Guidance. The article provides guidance on key provisions when negotiating clinical trial agreements (CTAs) on behalf of pharmaceutical companies.
Faget, co-chair of Foley’s Health Care and Life Sciences Practice Groups, covers topics such as the role of contract research organizations (CROs) in CTA negotiations, preamble, confidentiality, intellectual property, indemnification, subject injury, limitation on liability, and publication rights.
Author(s)
Related Insights
25 April 2024
On Trial
A Trial Lawyer’s Trial Lawyer: Paul Callan On Trial
In this episode of On Trial, host Christopher DeGennaro sits down with seasoned trial lawyer and CNN legal commentator Paul Callan, former deputy chief of the Brooklyn District Attorney’s Office, with 30 years’ experience as a trial lawyer.
25 April 2024
Health Care Law Today
New Favorable OIG Advisory Opinion Allows Patient Assistant Programs Funded by Drug Manufacturers
The Office of Inspector General recently issued a new favorable advisory opinion regarding patient assistance programs for 12 specific disease funds.
09 May 2024
Events
The FTC Noncompete Rule: Where Do We Go From Here?
On Tuesday, April 23, 2024, the Federal Trade Commission (FTC) voted to finalize a rule abolishing the vast majority of employee noncompetes across the United States.